Want to see HK:0950 full AI Analyst Report?
0950 Stock Chart & Stats
HK$1.55
-HK$0.01(-0.76%)
At close: 4:00 PM EST
HK$1.55
-HK$0.01(-0.76%)
Day’s Range― - ―
52-Week RangeHK$0.99 - HK$2.56
Previous CloseN/A
Volume7.00K
Average Volume (3M)850.08K
Market Cap
HK$712.49M
Enterprise ValueHK$312.98
Total Cash (Recent Filing)HK$364.39M
Total Debt (Recent Filing)HK$249.84M
Price to Earnings (P/E)4.3
Beta0.70
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.72%
Share Statistics
EPS (TTM)0.28
Shares Outstanding588,835,300
10 Day Avg. Volume512,350
30 Day Avg. Volume850,075
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio8.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue growth of approximately 30% indicates strong recent demand and expanding commercial activity across the company’s pharmaceutical portfolio. Sustained top-line momentum can support greater operating scale, product investment, regulatory activities, and broader market penetration over the next several quarters.
Healthy Product EconomicsA gross margin in the low-to-mid 50% range suggests the company’s products retain meaningful economic value after production costs. The improvement in net margin to about 8.6% also shows better earnings conversion, creating more capacity to support commercialization and research activities.
Conservative Balance SheetLow leverage and a sizable equity base provide financial flexibility for an integrated pharmaceutical business operating across research, registration, production, and sales. The conservative capital structure reduces refinancing pressure and improves resilience while allowing resources to remain available for growth initiatives.
Bears Say
Weak Operating ProfitWeak TTM EBIT compared with prior annual periods raises concern about the durability of operating earnings despite strong revenue growth. Profit volatility makes future performance harder to underwrite and suggests that product mix, operating costs, or commercialization economics may not yet be consistently favorable.
Inconsistent Free Cash FlowThe swing from negative to positive free cash flow indicates that cash generation has not been consistently dependable across periods. TTM free cash flow at roughly 72% of net income also points to variability from working-capital and capital-spending demands, which can constrain internally funded investment.
Uneven Return On EquityAlthough TTM ROE has improved, its historically uneven level indicates that the company has not consistently converted its capital base into strong shareholder returns. This may limit confidence in the repeatability of earnings performance and suggests that balance-sheet strength has not always translated into efficient profitability.
Lee's Pharmaceutical Holdings Limited News
0950 FAQ
What was Lee's Pharmaceutical Holdings Limited’s price range in the past 12 months?
Lee's Pharmaceutical Holdings Limited lowest stock price was HK$0.99 and its highest was HK$2.56 in the past 12 months.
What is Lee's Pharmaceutical Holdings Limited’s market cap?
Lee's Pharmaceutical Holdings Limited’s market cap is HK$712.49M.
When is Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date?
Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date is Mar 30, 2027 which is in 191 days.
How were Lee's Pharmaceutical Holdings Limited’s earnings last quarter?
Lee's Pharmaceutical Holdings Limited released its earnings results on Aug 31, 2026. The company reported HK$0.161 earnings per share for the quarter.
Is Lee's Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Lee's Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Lee's Pharmaceutical Holdings Limited pay dividends?
Lee's Pharmaceutical Holdings Limited pays a Semiannually dividend of HK$0.035 which represents an annual dividend yield of 3.72%. See more information on Lee's Pharmaceutical Holdings Limited dividends here
What is Lee's Pharmaceutical Holdings Limited’s EPS estimate?
Lee's Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lee's Pharmaceutical Holdings Limited have?
Lee's Pharmaceutical Holdings Limited has 588,835,300 shares outstanding.
What happened to Lee's Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Lee's Pharmaceutical Holdings Limited reported an EPS of HK$0.161 in its last earnings report. Following the earnings report the stock price went down -4.104%.
Which hedge fund is a major shareholder of Lee's Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0950
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lee's Pharmaceutical Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.71%
12-Months-Change
Fundamentals
Return on Equity
3.72%
Trailing 12-Months
Asset Growth
16.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―